HSP90β shapes the fate of Th17 cells with the help of glycolysis-controlled methylation modification.
Ling YangJing-Chao ZhuShi-Jia LiXi ZengXin-Ru XueYue DaiZhi-Feng WeiPublished in: British journal of pharmacology (2024)
HSP90β shapes the fate of Th17 cells via glycolysis-controlled methylation modification to affect UC progression, which provides a new therapeutic target for UC.